| Mountainside Therapy, Llc | |
|
4805 Hahns Peak Dr Unit 104, Loveland, CO 80538-6171 | |
| (484) 885-4785 | |
| Not Available |
| Full Name | Mountainside Therapy, Llc |
|---|---|
| Type | Facility |
| Speciality | Occupational Therapist - Pediatrics |
| Location | 4805 Hahns Peak Dr Unit 104, Loveland, Colorado |
| Accepts Medicare Assignments | Does not participate in Medicare Program. The facility may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1023880267 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 225XP0200X | Occupational Therapist - Pediatrics | (* (Not Available)) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Mountainside Therapy, Llc 4805 Hahns Peak Dr Unit 104, Loveland, CO 80538-6171 Ph: () - | Mountainside Therapy, Llc 4805 Hahns Peak Dr Unit 104, Loveland, CO 80538-6171 Ph: (484) 885-4785 |
News Archive
Cellectis, the French genome engineering specialist, has announced today that it has signed an exclusive license agreement with the University of Minnesota that grants Cellectis the worldwide right to use inventions related to TAL effector-mediated DNA recognition and cleavage. This revolutionary approach for the targeted modification of genomes was developed by the University of Minnesota and Iowa State University.
Watson Pharmaceuticals, Inc. today announced that its subsidiary, Watson Laboratories, Inc., has entered into an exclusive agreement with Ortho-McNeil-Janssen Pharmaceuticals, Inc. (OMJPI), to market the authorized generic version of Concerta® (methylphenidate hydrochloride extended-release tablets). Watson will launch its authorized generic of Concerta on May 1, 2011. Concerta is indicated for the treatment of attention deficit hyperactivity disorder (ADHD).
20/20 GeneSystems, Inc. announced today at the AdvaMed MedTech Conference in Washington, D.C. that the company has been awarded nearly $3 million in grants from the National Cancer Institute's (NCI) Small Business Innovative Research (SBIR) Program to develop tests to help oncologists predict the effectiveness of targeted cancer therapies.
Researchers at the University of Pittsburgh School of Medicine and Arts & Sciences have designed a more effective version of an FDA-approved epilepsy drug with the potential for fewer side effects, according to a study published on March 22 in Molecular Pharmacology. The experimental agent also could prove to be a treatment for tinnitus and other disorders caused by volatile neural signaling.
› Verified 6 days ago
Karlie Marie Lindgren, OTR Occupational Therapist Medicare: Medicare Enrolled Practice Location: 1875 Fall River Dr, Loveland, CO 80538 Phone: 970-461-1100 | |
Sarah Catherine Howell, OTD, OTR/L Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 3276 Bayfield Dr, Loveland, CO 80538 Phone: 970-203-1002 | |
Jennifer Franklin, MOTR L Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 407 E 42nd St, Loveland, CO 80538 Phone: 360-892-5142 Fax: 360-892-2157 | |
Andrea Swayze, Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 821 Duffield Ct, Loveland, CO 80537 Phone: 970-669-0345 | |
Abg Therapy & Wellness Center Occupational Therapist Medicare: Medicare Enrolled Practice Location: 3780 N Garfield Ave Ste 102, Loveland, CO 80538 Phone: 970-663-3222 Fax: 970-663-3227 | |
Maigen Marie Cummesky, OTR Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 3001 N Taft Ave, Ste. 100, Loveland, CO 80538 Phone: 970-663-3222 |